Lantern Pharma (NASDAQ:LTRN) Cut to Sell at Wall Street Zen

Wall Street Zen downgraded shares of Lantern Pharma (NASDAQ:LTRN) from a hold rating to a sell rating in a research note published on Saturday.

Separately, Weiss Ratings upgraded Lantern Pharma from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, July 29th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Lantern Pharma has a consensus rating of “Sell”.

Lantern Pharma Stock Down 1.9%

LTRN opened at $2.60 on Friday. The stock’s fifty day moving average is $3.29 and its two-hundred day moving average is $2.85. The company has a market capitalization of $33.18 million, a P/E ratio of -1.60 and a beta of 2.35. Lantern Pharma has a 52 week low of $1.11 and a 52 week high of $4.75.

Lantern Pharma (NASDAQ:LTRN) last issued its earnings results on Friday, August 14th. The company reported ($0.57) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.19).

Hedge Funds Weigh In On Lantern Pharma

Institutional investors have recently bought and sold shares of the business. Empery Asset Management LP bought a new position in Lantern Pharma in the second quarter worth approximately $3,513,930,000. BlackRock Inc. bought a new stake in Lantern Pharma during the 2nd quarter valued at $93,000. Bank of New York Mellon Corp purchased a new position in shares of Lantern Pharma in the 2nd quarter valued at $89,000. Renaissance Technologies LLC increased its holdings in shares of Lantern Pharma by 5.1% in the 1st quarter. Renaissance Technologies LLC now owns 116,000 shares of the company’s stock valued at $159,000 after acquiring an additional 5,600 shares during the period. Finally, Cetera Investment Advisers bought a new position in shares of Lantern Pharma in the 4th quarter worth $37,000. 28.62% of the stock is owned by hedge funds and other institutional investors.

Lantern Pharma Company Profile

Lantern Pharma, Inc is a clinical-stage oncology company leveraging artificial intelligence (AI) and machine learning to accelerate the discovery and development of targeted cancer therapies. Headquartered in Dallas, Texas, Lantern Pharma’s proprietary RADR® platform integrates large-scale genomic, transcriptomic and chemical data to identify novel drug candidates and predict patient populations most likely to benefit from treatment.

The company’s pipeline focuses on molecules designed to address cancers with high unmet medical need.